Home Magazines Editors-in-Chief FAQs Contact Us

The radiologic assessment of progressive disease for patients with hepatocellular carcinoma after transarterial chemoembolization should be stratified


Journal of Cancer Prevention & Current Research
Di-Min Liu,1 Zhong-Xing Luo,1 Xing-Kui Chen,1 Jia-Ping Li,2 Ying-Qiang Zhang1,2
Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, China
Di-Min Liu, Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-sen University, China
Zhong-Xing Luo, Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-sen University, China
Xing-Kui Chen, Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-sen University, China
Jia-Ping Li, Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, China

Abstract

Assessment of progression according to EASL or mRECIST after transarterial chemoembolization (TACE) has certain of limitations, mainly because of unspecified number of new lesions and primary tumor response was not considered. We retrospectively analyzed 105 HCC patients with progression after initial TACE. In the analysis, overall survival was significantly longer in subgroup with new lesions ≤3, primary tumor response, and decreased AFP than that with new lesions >3, non-primary tumor response, and increased AFP, respectively. Therefore, a comprehensive analysis of primary tumor response, along with number of new lesions and change of AFP, could make an accurate assessment.

Keywords

radiology, assessment, progressive disease, hepatocellular carcinoma, transarterial chemoembolization, primary tumor, mRECIST, EASL, hepatocellular carcinoma, progressive disease, epirubicin, serum AFP assay, hepatitis serologic test, Barcelona Clinic Liver Cancer, Cirrhosis, Etiology

Testimonials